Key facts
- The most common modafinil side effects in US clinical trials were headache, nausea, nervousness, a stuffy or runny nose, back pain, diarrhea, anxiety, trouble sleeping, dizziness and indigestion. New to this medicine? Start with our modafinil overview.
- About 8% of people in those trials stopped modafinil because of a side effect, compared with 3% on placebo. Headache was the top reason.
- Serious skin reactions, including Stevens-Johnson syndrome, are rare but can be life-threatening. The FDA label says to stop modafinil at the first sign of a rash unless it is clearly unrelated.
- Modafinil can make hormonal birth control less effective during treatment and for one month after the last dose.
- Modafinil is a Schedule IV controlled substance in the US and is approved only for adults.
Most people who take modafinil (brand name Provigil) for narcolepsy, obstructive sleep apnea or shift work disorder have mild side effects or none at all. A small number have reactions that need fast medical care. This guide walks through modafinil side effects the way the US prescribing information for Provigil describes them: how often each one happened in trials, which ones are warning signs, and what to do next. For a full overview of what the medicine is and how it works, start with our modafinil guide.
How common are modafinil side effects?
The clearest numbers come from the pooled placebo-controlled trials in the FDA label, which included 934 adults on modafinil and 567 on placebo. Comparing the two groups matters, because some symptoms (like headache) are common even in people taking a dummy pill. The table shows the side effects reported by at least 5% of people on modafinil.
| Side effect | Modafinil | Placebo |
|---|---|---|
| Headache | 34% | 23% |
| Nausea | 11% | 3% |
| Nervousness | 7% | 3% |
| Runny or stuffy nose (rhinitis) | 7% | 6% |
| Back pain | 6% | 5% |
| Diarrhea | 6% | 5% |
| Anxiety | 5% | 1% |
| Dizziness | 5% | 4% |
| Indigestion (dyspepsia) | 5% | 4% |
| Trouble sleeping (insomnia) | 5% | 1% |
Less often, people reported loss of appetite, dry mouth, sore throat, chest pain, high blood pressure, a pounding or fast heartbeat, tingling skin and a low mood, each in roughly 2% to 4% of people on modafinil. In those studies, headache and anxiety became more likely as the dose went up.
The label reports that 8% of people taking modafinil stopped because of a side effect, versus 3% on placebo. Headache was the most frequent reason, followed by nausea, anxiety, dizziness, insomnia, chest pain and nervousness.
Common side effects and what usually helps
Headache
Headache is the side effect people notice most, and it tends to show up in the first days of treatment. If headaches are frequent or severe, tell your prescriber rather than changing the dose yourself.
Nausea, indigestion and appetite changes
Some people feel queasy or lose their appetite. Taking the dose at the same time each morning, with a light breakfast, is a common practical step.
Trouble sleeping
Modafinil is a wakefulness-promoting medicine, so taking it later in the day can keep you up at night. The FDA label directs a single morning dose for narcolepsy and sleep apnea, and a dose about one hour before the work shift for shift work disorder. If your sleep is getting worse, ask your prescriber whether the timing fits your schedule.
Nervousness, anxiety and jitteriness
Feeling wired or on edge is more common than with placebo and can be dose-related. MedlinePlus lists anxiety among the symptoms to report promptly, so mention it even if it seems minor.
Rare but serious modafinil side effects
These reactions are uncommon. They are the reason modafinil is a prescription medicine that needs follow-up visits.
Serious skin rash (SJS, TEN and DRESS)
The label’s first warning covers rash. Rare cases of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported in adults and children. Key points from the prescribing information:
- Nearly all serious rashes appeared within 1 to 5 weeks of starting modafinil, though a few happened after about 3 months.
- In pediatric trials, about 0.8% of children (13 of 1,585) stopped because of a rash. This is one reason modafinil is not approved for anyone under 17.
- No known factor predicts who will have a serious rash, and a mild rash cannot be reliably told apart from a dangerous one early on.
Because of this, the label says modafinil should be stopped at the first sign of a rash unless the rash is clearly not drug-related. Do not wait to see if it spreads. Contact your prescriber the same day.
Allergic swelling and multi-organ reactions
Angioedema (swelling of the face, lips, tongue or throat) has been reported after approval. A rare reaction called multi-organ hypersensitivity, including at least one death, usually appeared about two weeks after starting (range 4 to 33 days). It typically begins with fever and rash and can affect the heart, liver or blood counts.
Mental health changes
In US trials, anxiety, nervousness, confusion, agitation and depression led a small number of people to stop. Reports after approval include mania, delusions, hallucinations, suicidal thoughts and aggression, some needing hospital care. Many, but not all, of those people had a prior psychiatric history. A published case report describes psychosis in a young adult with no psychiatric history, which resolved after modafinil was stopped and treatment was given. If you have a history of psychosis, depression or bipolar disorder, your prescriber needs to know before you start.
Heart and blood pressure effects
Chest pain, palpitations and a fast heartbeat were reported in trials. The FDA label says modafinil is not recommended for people with left ventricular hypertrophy, or with mitral valve prolapse who previously had chest pain, ECG changes or arrhythmia on a stimulant. In trials, 2.4% of people on modafinil needed new or increased blood pressure medicine, compared with 0.7% on placebo, so your prescriber may check your blood pressure and heart rate more often.
Lingering sleepiness
Modafinil may not bring alertness fully back to normal. Avoid driving or hazardous work until you know how it affects you.
When to get emergency help: Call 911 for trouble breathing or swallowing, swelling of the face, lips, tongue or throat, chest pain with shortness of breath, fainting, or a seizure. Stop modafinil and get same-day medical care for any rash, blisters, peeling skin, mouth sores or hives, especially with fever. For hallucinations, a sudden extreme mood change or thoughts of self-harm, call your prescriber now, or call or text 988 (Suicide and Crisis Lifeline). If someone may have taken too much, call Poison Help at 1-800-222-1222.
Birth control, pregnancy and breastfeeding
Modafinil speeds up how the body clears some hormones. The FDA label says hormonal contraceptives, such as pills containing ethinyl estradiol, may be less effective while you take modafinil and for one month after you stop. Use a backup or alternative method during that time and ask your prescriber which options suit you.
There are no well-controlled studies in pregnant women. The label notes reports of restricted fetal growth and miscarriage with modafinil and the closely related armodafinil, though it is unknown whether the drug caused them. Animal studies showed developmental harm. Tell your prescriber if you are pregnant, planning a pregnancy or breastfeeding. The manufacturer runs a pregnancy registry at 1-866-404-4106.
Other interactions that can cause side effects
Modafinil can change levels of other medicines. The label highlights cyclosporine (levels may drop) and drugs processed by the CYP2C19 enzyme, such as omeprazole, phenytoin and diazepam (levels may rise). People on warfarin may need more frequent INR checks. MedlinePlus advises avoiding alcohol while taking modafinil. Give your prescriber and pharmacist a full list of your medicines and supplements.
Misuse, dependence and stopping
Modafinil is listed in Schedule IV by the DEA, which means it has a recognized, lower potential for misuse. In a study of people experienced with drugs, it produced euphoric and stimulant-like effects similar to methylphenidate. In one 9-week trial, people had no withdrawal symptoms in the 14 days after stopping, though sleepiness returned in those with narcolepsy. Talk to your prescriber before stopping or changing your dose.
Who has a higher risk of side effects?
- Older adults: the body may clear modafinil more slowly, and the label suggests considering lower doses with close monitoring.
- Severe liver impairment: the label calls for half the usual dose.
- Heart disease or high blood pressure: closer monitoring is advised.
- A history of mental health conditions or substance use: your prescriber may follow you more closely.
- A past rash from any medicine: mention it before starting.
Questions to ask your prescriber
- Which modafinil side effects should I expect in the first few weeks, and which mean I should call you?
- What should I do if I notice a rash, even a mild one?
- Do I need a blood pressure check or an ECG before or during treatment?
- Does modafinil interact with my birth control or any of my other medicines?
- What time of day should I take it so it does not affect my sleep?
- Is it safe for me to drive while I am getting used to this medicine?
You can also report side effects to the FDA through MedWatch or by calling 1-800-FDA-1088.
Frequently asked questions
What is the most common side effect of modafinil?
Headache. In US clinical trials it affected 34% of people on modafinil compared with 23% on placebo, and it was the most common reason people stopped treatment.
Do modafinil side effects go away?
Mild effects such as headache, nausea and jitteriness often ease as your body adjusts. Tell your prescriber about any side effect that is severe or does not go away, and stop the medicine and seek care right away for a rash or allergic swelling.
Can modafinil cause a rash?
Yes. Most rashes are mild, but rare cases of Stevens-Johnson syndrome, toxic epidermal necrolysis and DRESS have been reported, usually within 1 to 5 weeks of starting. The FDA label says to stop modafinil at the first sign of a rash unless it is clearly unrelated.
Does modafinil affect birth control?
Yes. Hormonal birth control may be less effective while taking modafinil and for one month after stopping it, so a backup or alternative method is recommended during that time.
Can modafinil raise blood pressure or heart rate?
It can. In trials, more people on modafinil needed new or increased blood pressure medicine than on placebo, and palpitations and a fast heartbeat were reported. People with heart disease may need closer monitoring.
Related guides
- Modafinil Explained: Uses, How It Works and Safety
- Modafinil vs Armodafinil: What’s the Difference?
- Modafinil vs Adderall (and Vyvanse, Ritalin): How They Differ
- Zopiclone: What It Is and Why It Isn’t Sold in the US
- How to Buy Modafinil for Narcolepsy Treatment (Prescription Required)
- Modafinil for Narcolepsy: How It Treats Excessive Daytime Sleepiness
- Modafinil for Idiopathic Hypersomnia, ADHD and MS Fatigue: What the Evidence Says
- Is Modafinil a Controlled Substance? Schedule IV Explained
- How Modafinil Works: Mechanism, Half-Life and How Long It Lasts
- Modafinil Dosage: What the FDA Label Says
- Modafinil Interactions: Alcohol, Birth Control and Caffeine
- The “Smart Drug” Myth: Modafinil in Healthy People
- How to Get a Modafinil Prescription: Sleep Studies, Telehealth and Insurance
Sources
- Provigil (modafinil) tablets: prescribing information, revised 12/2022. DailyMed, US National Library of Medicine.
- US Food and Drug Administration. Provigil (modafinil) prescribing information (Drugs@FDA).
- National Library of Medicine. Modafinil: MedlinePlus Drug Information.
- Aytas O, Yalvac HD. Modafinil-induced psychosis: a case report. Archives of Neuropsychiatry, 2015 (PubMed Central).
- Drug Enforcement Administration, Diversion Control Division. Controlled Substances: Alphabetical Order.
- US Food and Drug Administration. MedWatch: The FDA Safety Information and Adverse Event Reporting Program.
